EACS2023: 658 Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide(BIC/FTC/TAF) as switch strategy in virologically suppressed: real world data from monocentric cohort R.A. Passerotto , F. Lamanna , D. Farinacci , A. Dusina , A. D'Angelillo , A. Ciccullo , G. Baldin , I. Mozzetta , E. Visconti , S. Di Giambenedetto , A. Borghetti Università Cattolica del Sacro Cuore, Rome, Italy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Ospedale San Salvatore, L'Aquila, Italy General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: We evaluated BIC/FTC/TAF effectiveness as switch strategy in virologically-suppressed in real-life. Method: A retrospective monocentric cohort including virologically-suppressed (HIV-RNA<50 cp/mL) patients switching to TAF/FTC/BIC in 2018-2022 was performed. Probabilities of virological failure (VF, i.e. 2 consecutive HIV-RNA ≥ 50 cp/mL or single HIV-RNA ≥ 200 cp/mL) and of treatment discontinuation (TD) were estimated by Kaplan-Meier. Predictors of both outcomes were identified through Cox regression. Analysis-of-variance for repeated measures was used to examine changes in CD4-to-CD8 ratio from baseline up to 36 months and predictors of its variation were analyzed through linear regression. Results: Overall, 16 VF occurred during 22 months of median follow-up. Estimated probabilities of VF at 1, 2 and 3 years were 2.0% (95% CI 1.0-4.2%), 2.9% (95% CI 1.5-5.6%), 5.5% (95% CI 3.2-9.2%). Caucasian ethnicity (versus others, aHR 0.32, 95% CI 0.11-0.94; p= 0.039) and previous VF (versus none, aHR 10.06, 95% CI 1.32-76.56; p = 0.026) independently predicted VF. Particularly, switch from any prior drug class didn't predict VF. Overall, 42 TD occurred: predominantly for simplification, followed by toxicity and one for VF. No predictors of TD were identified; the safety was similar across different pre-switch strategies. An increase in CD4-to-CD8 ratio over 3 years was evidenced (p<0.001). Previous AIDS-event (versus none, B: -0.09, 95% CI -0.17; 0.00; p=0.047) and longer time of virological suppression (per 1 year more, B: -0.02, 95% CI - 0.03; -0.01; p<0.001) were associated with a reduction in delta CD4-to-CD8 at 12 months. Total cholesterol decreased over 3 years (p<0.001). Higher zenith HIV-RNA predicted a lower decrease (>500,000cp/mL versus<100,000cp/mL, B:+16.9; 95% CI +5.4; +28.4; p=0.004), whereas switching from a 2-drug regimen (versus a 3-drug regimen, B: -15.3; 95% CI -29.4; -1.13; p=0.034) was associated with greater decrease. Triglycerides didn't change over time (p=0.465). Patients’ characteristics are in table 1. Conclusions: BIC/FTC/TAF demonstrated effectiveness, tolerability and safety. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 2 1 3 2 2 2 1,2 2 1 2 3 144 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=